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Abstract
Background: Induction of pro-inflammatory factors is one of the characteristics of microglia activation and can be
regulated by numerous active components of Chinese traditional herbs. Suppression of pro-inflammatory factors is
beneficial to alleviate microglia-mediated cell injury. The present study aims to investigate the effect and possible
mechanism of 2,3,4’,5-tetrahydroxystilbene 2-O-β-D-glucoside (TSG) on LPS-mediated induction of pro-inflammatory
factors in microglia.
Methods: Western blot, ELISA, and Hoechst 33258 were used to measure the protein expression, TNF-α/IL-6
content, and apoptotic nuclei, respectively. The mRNA level was measured by real time-PCR. Nitric oxide (NO)
content, lactate dehydrogenase (LDH) content, and NF-κB binding activity were assayed by commercial kits.
Results: TSG reduced iNOS protein expression as well as TNF-α, IL-6, and NO content in LPS-stimulated BV-2 cells.
TSG attenuated the increase in apoptotic nuclei, caspase-3 cleavage, and LDH content induced by BV-2 cell-derived
conditioned medium in primary hippocampal neurons. Mechanistic studies showed that TSG reduced the mRNA
level of iNOS, TNF-α, and IL-6. TSG failed to suppress IκB-α degradation, NF-κB phosphorylation and nuclear
translocation, and ERK1/2, JNK, and p38 phosphorylation. TSG, however, markedly reduced the binding of NF-κB to
its DNA element. Chromatin immunoprecipitation (ChIP) assays confirmed that TSG reduced NF-κB binding to the
iNOS promoter. These findings were ascertained in primary microglia where the LPS-induced increase in iNOS
expression, NO content, apoptotic nuclei, and NF-κB binding to its DNA element were diminished by TSG.
Conclusions: These studies demonstrate that TSG attenuates LPS-mediated induction of pro-inflammatory factors
in microglia through reducing the binding activity of NF-κB. This might help us to further understand the
pharmacological role of TSG in inflammatory response in the central nervous system.
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Background
Microglia are the resident immune cells in the central ner-
vous system (CNS). They serve as the neuron-pathological
sensor under various conditions such as inflammation
[1,2]. The sensing of microglia to pathological stimuli
leads to activation of microglia, which then produce
trophic factors that are important for neuronal recovery
[3]. However, uncontrolled activation of microglia triggers
neurotoxicity by overproducing cytokines such as nitric
oxide (NO), TNF-α, and IL-6 [4-6]. NO is synthesized
by a family of NO synthase (NOS) consisting of three
isoforms: endothelial NOS (eNOS), neuronal NOS
(nNOS), and inducible NOS (iNOS) [7]. NO generated
from eNOS and nNOS primarily participates in cardiovas-
cular regulation, neuronal signaling transduction, and
neuronal protection [8-10]. NO produced from iNOS [11],
however, promotes the development of neurodegenerative
disorders associated with inflammation such as Parkinson’s
disease and multiple sclerosis [12,13]. Similarly, TNF-α and
IL-6 also have dual functions. For example, TNF-α
preconditioning was found to protect neurons from Aβ-
mediated cell toxicity [14]. IL-6 treatment ameliorates
trimethyltin-induced injury in neurons [15]. Both TNF-α
and IL-6 were confirmed to enhance neurotoxicity [5,6].
Collectively, control of induction of cellular cytokines in
microglia might be important for regulation of numerous
physiological or pathological processes.
An important feature of pro-inflammatory factors is their
absence in quiescent inflammatory cells and induction by
inflammatory inducers. Lipopolysaccharide (LPS) is an ex-
tensively characterized inducer of pro-inflammatory factors
[16]. It stimulates gene transcription of pro-inflammatory
factors through the classical inhibitor of κB kinase (IKK)-
inhibitor of κB α (IκB-α)-nuclear factor κB (NF-κB) signal-
ing pathway. LPS binds with the Toll-like receptors leading
to IκB-α degradation through the ubiquitin-proteasome
system [17]. The removal of IκB-α liberates transcriptional
factor NF-κB. The active NF-κB is then free for transloca-
tion to the nucleus, where it initiates gene transcription
[17]. Besides IκB-α-NF-κB signals, mitogen-activated pro-
tein kinase (MAPK) including ERK1/2, p38, and JNK is
also involved in induction of pro-inflammatory factors
[18-20]. Interfering with the MAPK signals is beneficial to
coping with inflammation.
Plenty of small molecules extracted from traditional
Chinese herbal medicines have been reported to regulate
induction of pro-inflammatory factors through the classical
IκB-α-NF-κB pathway. For instance, oregonin was found
to inhibit iNOS gene transcription by reducing the nuclear
translocation of NF-κB in LPS-stimulated microglia [21];
curcumin suppresses the expression of NF-κB-dependent
genes in rats [22]. A monomer of stilbene from a trad-
itional Chinese herbal medicine polygonummultiflorum,
2,3,4’,5-tetrahydroxystilbene 2-O-β-D-glucoside (TSG), has
also been found to attenuate inflammatory responses [23].
Its anti-inflammatory function was supported by the fol-
lowing evidence: 1) TSG suppresses COX-2 expression in
a carrageenin-induced rat paw edema model [24]; 2) TSG
reduces NO levels in serum and the aorta in atheroscler-
otic rats [25]; and 3) TSG decreases iNOS expression and
infarct volume in the ischemic brain [26]. In the third case,
the effect of TSG was explained by the suppression of NF-
κB nuclear translocation in neurons but not in microglia
[26]. In the present study, in view of the great importance
of microglia in CNS disorders associated with inflamma-
tion [27,28], we explored the effect and mechanism of TSG
on LPS-mediated inflammatory response in microglia. We
found that TSG reduces iNOS expression and NO, TNF-α,
and IL-6 release in microglia in a way that is independent
of MAPK-IκB-α-NF-κB activation but likely represses NF-
κB binding activity.
Methods
Chemicals and reagents
DMEM/F12 was obtained from Gibco Invitrogen Cor-
poration (Carlsbad, CA, USA). Heat-inactivated FBS was
purchased from Hyclone (Logan, UT, USA). TSG was
the product of the National Institute for the Control of
Pharmaceutical and Biological Products (Beijing, China).
LPS, poly-L-lysine, and Hoechst 33258 were purchased
from Sigma (Saint Louis, MO, USA). Antibodies against
iNOS, IκB-α, p-NF-κB, NF-κB, Histone H2A, ERK1/2,
phospho-ERK1/2, and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) were purchased from Cell Sig-
naling Technology (Beverly, MA, USA). Protein A/G
PLUS-Agarose and antibodies against caspase-3, p38,
phospho-p38, JNK, and phospho-JNK were the products
of Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Other related agents were purchased from commercial
suppliers. All drugs were prepared as stock solutions,
and stock solutions were stored at −20°C.
Cell preparation
BV-2 cells were grown in DMEM/F12 with 10% FBS.
The use of mice was approved by the University Animal
Ethics Committee of Nantong University (Permit Number:
2110836). Mouse primary cultured brain cells were pre-
pared as described previously with some modifications
[29]. Briefly, newborn (day 0 to 1) C57/BL6 mice were
decapitated, hippocampus were then removed and
digested with 0.125% trypsin for 15 minutes at 37°C.
Followed by trituration and centrifugation at 118 g for
6 minutes, cells were re-suspended and plated on poly-
L-lysine (1 mg/mL)-coated culture flasks. For preparation
of hippocampal neurons, the single-cell suspension was
cultured in DMEM/F12 supplement with 2% B27 and 1%
penicillin-streptomycin (100 U/mL), and the medium was
replaced every 3 days. For preparation of primary
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microglia, the individual cell suspensions were cultured in
DMEM/F12 supplement with 10% FBS and 1% penicillin-
streptomycin (100 U/mL). This medium was replaced
every 3 days. After 12 days, mixed cells were shaken gently
overnight (37°C, 18 h), and the supernatants were col-
lected and plated on the new poly-L-lysine-coated culture
flasks. All cells were maintained in a 37°C incubator
containing 95% air and 5% CO2.
Cell viability assay
Cell viability was measured using MTT Cell Prolifera-
tion and Cytotoxicity Assay Kit (Bi Yuntian Biological
Technology Institution, Shanghai, China). Briefly, methylt-
hiazolyldiphenyl-tetrazolium bromide (5 mg/mL) was
dissolved in prepared MTT-dissolved solutions and
kept at −20°C. After washing with PBS, the cells in
plates were added 20 μL of MTT solutions and kept at
37°C for 4 h. The blue crystals were dissolved in formazan-
dissolved solutions. The absorbance was read at 570 nm.
Western blot
To extract the total proteins, cells were lysed on ice for
30 minutes in lyses buffer (50 mM Tris–HCl, pH 7.4,
1 mM EDTA, 100 mM NaCl, 20 mM NaF, 3 mM
Na3VO4, 1 mM PMSF with 1% (v/v) Nonidet P-40, and
protease inhibitor cocktail). The lysates were centrifuged
at 12,000 g for 16 minutes, and the supernatants were
harvested. After denaturation, 30 μg of protein was sepa-
rated on 10% SDS/PAGE gels and then transferred to
nitrocellulose membranes (Bio-Rad, Hercules, CA,
USA). After blocking with 5% nonfat dried milk powder/
Tris-buffered saline Tween-20 (TBST) for 1 h, mem-
branes were probed with 1:500 primary antibodies against
iNOS, caspase-3, IκB-α, p-NF-κB, NF-κB, ERK1/2, p-ERK1/
2, JNK, p-JNK, p38, p-p38, and Histone H2A or 1:10,000
primary antibody against GAPDH overnight at 4°C. Pri-
mary antibodies were then removed by washing the
membranes three times in TBST. Membranes were fur-
ther incubated for 2 h at room temperature with IRDye
680-labeled secondary antibodies (1:3,000 to 1:5,000).
Finally immunoblots were visualized by scanning using
the Odyssey CLx western blot detection system. Isolated
cytoplasmic and nuclear proteins were normalized to
GAPDH and Histone-H2A respectively. The band density
was quantified using Image J software.
Real-time PCR
At the end of each treatment, total RNA was isolated
from BV-2 cells using the RNeasy mini kit according
to the manufacturer’s instructions (Qiagen, GmbH,
Hilden, Germany). First-strand cDNA was generated
by reverse transcription of total RNA using the RT sys-
tem (Promega, Madison, WI, USA). Real-time PCR re-
actions were conducted with FaststartSYBR Green
Master Mix (Roche Molecular Biochemicals, Shanghai,
China). Briefly, 2 μL of diluted cDNA, 0.5 μM primers,
2 mM MgCl2, and 1 × FastStartSYBR Green Master
mix were employed. The primers are quoted as follows
[30,31]: iNOS 5’-CTC ACT GGGACAGCA CAG AA-3’
(forward), 5’-TGG TCA AAC TCT TGG GGT TC-3’
(reverse); TNF-α 5’-CTG TGA AGG GAA TGG GTG
TT-3’ (forward), 5’-GGT CAC TGT CCC AGC ATC TT-
3’ (reverse); IL-6 5’-TTC CAT CCA GTT GCC TTC TT-3’
(forward), 5’-CAG AAT TGC CAT TGC ACA AC-3’
(reverse); 18S rRNA 5’-GTA ACCCGTTGAACC CCA
TT-3’ (forward), 5’-CCA TCCAATCGG TAG TAG CG-3’
(reverse). PCR products were detected by monitoring the
fluorescence increase of double-stranded DNA-binding
dye SYBR Green during amplification. The expression
levels of target genes were normalized to the housekeep-
ing gene (18S rRNA). The fold changes in the target gene
expression between experimental groups were expressed
as a ratio. Relative gene expression was calculated by the
comparative cycle threshold (Ct) method. Melt-curve ana-
lysis and agarose gel electrophoresis were used to examine
the authenticity of the PCR products.
Detection of NO
Total nitrite levels in collected supernatants were mea-
sured with a Griess reagent kit (Invitrogen). The reaction
consisted of 20 μL of Griess Reagent, 150 μL of super-
natant, and 130 μL of de-ionized water. After incubation
of the mixture for 30 minutes at room temperature, ni-
trite levels were measured at 548 nm using an M2 spec-
trophotometric microplate reader (Molecular Devices).
Measuring of lactate dehydrogenase (LDH)
For LDH testing, hippocampal neurons were seeded into
24-well plates. BV-2 cells were treated with LPS (2 μg/mL)
for 24 h, and then the supernatants were collected to
incubate hippocampal neurons. After additional 48 h,
the supernatants from hippocampal neurons were col-
lected to be prepared for further experiments. LDH
levels were determined using LDH Cytotoxicity Assay Kit
according to the supplier’s recommendation (Bi Yuntian
Biological Technology Institution, Shanghai, China).
Hoechst 33258 staining
For Hoechst 33258 staining, hippocampal neurons in
different groups were fixed with 2% paraformaldehyde in
0.01 M PBS (pH 7.4) for 20 minutes, and then rinsed
three times with PBS for 10 minutes each. Cells were
treated with Hoechst 33258 staining solution for 15 minutes
at 4°C. The images of Hoechst 33258 staining were
viewed with a Nikon Eclipse 800 microscope. Cells with
condensed bright nuclei were regarded as apoptotic
cells. The apoptosis rate was calculated by the ratio be-
tween the numbers of cells with condensed bright
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nuclei and total cell numbers. The numbers of apoptotic
or total cells were counted from the resulting four phases
for each point with the digital camera and microscope,
and then averaged for each experimental condition. The
data presented were generated from three separate assays.
NF-κB binding assays
The nuclei were extracted from BV-2 cells or primary
microglia by first incubating them in hypotonic buffer
(10 mM Tris–HCl, pH 7.5, 10 mM NaCl, 1.5 mM
MgCl2) at 4°C for 15 minutes. After homogenization, cell
homogenates were spun at 3,000 g for 5 minutes. The
supernatants were collected for western blot analysis.
The pellets were recovered, extensively washed, and re-
suspended in the nuclear extraction buffer (50 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40,
0.25% sodium deoxycholate, 10% glycerol, 50 mM NaF,
1 mM Na3VO4, 5 mM sodium pyrophosphate, protease
inhibitors). The NF-κB binding activity of nuclear extracts
was measured with the TransFactor NF-κB colorimetric
kit (Clontech, Mountain View, CA, USA) according to the
manufacturer’s instruction.
Chromatin immunoprecipitation (ChIP)
The ChIP experiment was performed as described previ-
ously with some modifications [32]. Briefly, BV-2 cells
were treated with LPS (2 μg/mL) for 1 h in the presence
and absence of TSG. 1% of formaldehyde was added to
the culture medium, and after incubation on the rocker
for 10 minutes at room temperature, cells were rinsed
twice with PBS and lysed for 15 minutes at 4°C. After
sonication, the lysate was used as DNA input control.
The remaining lysates were diluted 10-fold with ChIP di-
lution buffer followed by incubation with NF-κB p65
antibody overnight at 4°C. Immunoprecipitated com-
plexes were collected using protein A/G Plus-agarose
beads. The precipitates were extensively washed and
then incubated in the elution buffer containing 1% SDS
and 0.1 M NaHCO3 at room temperature for 20 minutes.
Cross-linking of protein-DNA complexes was reversed
at 65°C for 4 h. DNA was extracted with the QiagenPCR
purification kit. For ChIP assays, we used the following
primers (forward) 5’-CAAGCCAGGGTATGTGGTTT-3’
and (reverse) 5’-GCAGCAGCCATCAGGTATTT-3’ to
get a fragment at 290-bp. The resulting product was sep-
arated by 2% agarose gel electrophoresis.
Statistical analysis
Data are expressed as means ± standard error (SE). One-
way analysis of variance (ANOVA) followed by the post
hoc test was used for the statistical analysis, employing
SPSS 11.0 software. Differences were considered signifi-
cant at P < 0.05.
Results
TSG suppresses the induction of pro-inflammatory factors
in LPS-stimulated BV-2 cells
To determine the working concentration and effective
period of TSG for induction of pro-inflammatory fac-
tors, we first investigated the dose- and time-dependent
effects of TSG on iNOS expression in BV-2 cells. BV-2
cells were pretreated with TSG for 30 minutes at con-
centrations range at 1 to 50 μM when 2 μg/mL of LPS
was applied to induce iNOS expression. As shown in
Figure 1A and 1B, TSG significantly reduced the in-
crease in iNOS expression in LPS-stimulated (2 μg/mL,
24 h) BV-2 cells. Peak inhibition was observed at the
concentration of 50 μM. For this reason, 50 μM of TSG
was selected for the following experiments. A time-
dependent response curve showed that pretreatment of
BV-2 cells with TSG (50 μM, 30 minutes) markedly
inhibited the increase in iNOS expression at the time
points of 16 and 24 h (Figure 1C and D). The cell viabil-
ity of BV-2 cells was not affected by TSG administration
at 1 to 100 μM (Figure 1E). Consistent with the effect
on iNOS expression, production of NO was also de-
creased by TSG treatment (50 μM, 30 minutes) in LPS-
stimulated BV-2 cells: the content of NO was decreased
from 22.93 ± 0.19 to 14.89 ± 1.16 (n = 6, P < 0.05 versus the
LPS alone-treated group, Figure 2A). Finally, we observed
a considerable reduction in TNF-α (from 286.65 ± 38.55 to
100.54 ± 13.42, n = 6, P < 0.05 versus the LPS alone-treated
group) and IL-6 (from 4763.40 ± 529.09 to 2479.38 ±
706.54, n = 6, P < 0.01 versus the LPS alone-treated group)
content after TSG treatment (50 μM, 30 minutes) in
LPS-stimulated BV-2 cells (Figure 2B and C).
TSG prevents primary hippocampal neuron injury
induced by BV-2 cell-derived conditioned medium
To further investigate whether the TSG-mediated sup-
pression of pro-inflammatory factors in BV-2 cells has
protective roles in neuronal damage, primary hippocam-
pal neurons were incubated with BV-2 cell-derived con-
ditioned medium in the absence or presence of TSG.
We found that without TSG treatment, the conditioned
medium induced a marked increase in apoptotic nuclei
percentage (Figure 3A and B), cleaved caspase-3 level
(Figure 3C and D), and LDH content in primary hippo-
campal neurons (Figure 3E). After TSG treatment (50 μM,
48 h), the percentage of apoptotic nuclei, the level of
cleaved caspase-3, and the content of LDH were decreased
from 251.17 ± 26.59%, 2.57 ± 0.43, and 5801.10 ± 631.62 in
LPS-stimulated cells to 142.91 ± 20.33% (n = 5, P < 0.05
versus the LPS alone-treated group), 1.81 ± 0.16 (n = 3,
P < 0.05 versus the LPS alone-treated group), and
3839.26 ± 906.27 (n = 6, P < 0.05 versus the LPS alone-
treated group) in LPS/TSG co-treated cells, respect-
ively. These results suggest that inhibition of induction
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of pro-inflammatory factors by TSG might contribute
to the amelioration of neuronal injury induced by
microglia-conditioned medium.
TSG reduces gene expression of pro-inflammatory factors
in LPS-stimulated BV-2 cells
The reduction of pro-inflammatory factors protein could
be due to the suppression of either gene transcription or
protein translation. In order to differentiate between the
two possibilities, we detected the mRNA level of iNOS,
TNF-α, and IL-6 in LPS (2 μg/mL, 24 h)-stimulated BV-2
cells in the absence or presence of TSG by real time-PCR.
As shown in Figure 4, LPS induced a robust increase in
iNOS, TNF-α, and IL-6 mRNA level. Pre-treatment of
cells with TSG (50 μM, 30 minutes) significantly decreased
the mRNA level of iNOS (from 8.94 ± 1.06 to 3.83 ± 0.85,
n = 3, P < 0.05 versus the LPS alone-treated group), TNF-α
(from 6.66 ± 0.84 to 2.96 ± 0.33, n = 3, P < 0.05 versus the
LPS alone-treated group), and IL-6 (from 9.95 ± 1.62 to
4.58 ± 0.65, n = 3, P < 0.05 versus the LPS alone-treated
group) in LPS-stimulated cells (Figure 4). These data sug-
gest that TSG exerts its inhibitory function likely by
reducing gene transcription of pro-inflammatory factors
in BV-2 cells.
TSG does not impact MAPK-IκB-α-NF-κB activation in
LPS-stimulated BV-2 cells
The IKK-IκB-α-NF-κB signaling pathway is widely ac-
cepted to mediate the induction of pro-inflammatory
factors in inflammation [17]. Therefore, to explore the
mechanism underlying the effect of TSG on gene tran-
scription of pro-inflammatory factors, we measured the
change in degradation of IκB-α after TSG treatment in
LPS-stimulated BV-2 cells. As shown in Figure 5A and
5B, LPS resulted in a dramatic increase in IκB-α degrad-
ation at the time point of 10 minutes, and TSG pretreat-
ment (50 μM, 30 minutes) did not alter this degradation.
It has been reported that the full activity of NF-κB needs
the increase of NF-κB phosphorylation. We therefore de-
termined whether TSG affects the LPS-triggered NF-κB
phosphorylation in BV-2 cells. In accordance with the
influence of TSG in IκB-α degradation, TSG treatment
(50 μM) failed to reduce the increase in the phosphoryl-
ation level of NF-κB p65 at Ser536 in LPS-stimulated
Figure 1 Effects of TSG on induction of inducible nitric oxide (iNOS) protein in BV-2 cells stimulated with lipolysaccharide (LPS).
(A) Representative images showing that TSG pretreatment (30 minutes) inhibited iNOS expression in LPS-stimulated BV-2 cells at different concentrations
(1, 10, 30, 50 μM). (B) Quantitative analysis of iNOS expression in cells upon LPS/TSG treatment (*P < 0.05 versus control). (C) Representative images
showing the time-dependent effect of TSG on iNOS expression in LPS-stimulated BV-2 cells. (D) A time-course analysis of iNOS expression upon TSG
incubation (*P< 0.05, **P< 0.01 versus control). (E) Quantitative analysis of the cell viability after TSG treatment at concentrations ranging from 1 to
50 μM (n = 6). All data were shown as mean ± standard error. Experiments were performed three times independently. NS, no significance; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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Figure 3 Role of TSG in injury of hippocampal neurons induced by BV-2 cell-derived conditioned medium. (A) Pretreatment with TSG
(30 minutes, 50 μM) inhibited the increase in apoptotic nuclei in primary hippocampal neurons stimulated with BV-2 cell-derived conditioned
medium. (B) Quantitative analysis of apoptotic nuclei percentage in neurons (n = 5, **P < 0.01 versus control; *P < 0.05 versus the lipopolysaccharide
(LPS) alone-treated group). (C) Representative images showing that TSG pretreatment (50 μM, 30 minutes) reduced the cleavage of caspase-3 in
primary hippocampal neurons stimulated with BV-2 cell-derived conditioned medium. (D) Quantitative analysis of cleaved caspase-3 in neurons
(n = 3, *P < 0.05 versus control or the LPS alone-treated group). (E) Quantitative analysis of lactate dehydrogenase (LDH) content in LPS/TSG-treated
hippocampal neurons (n = 6, **P < 0.01 versus control; *P < 0.05 versus the LPS alone-treated group). All data were shown as mean ± standard error.
NS, no significance; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Figure 2 Effects of TSG on release of nitric oxide (NO), TNF-α, and IL-6 in BV-2 cells stimulated with lipolysaccharide (LPS). Quantitative
analysis of NO (A), TNF-α (B), and IL-6 (C) content after TSG treatment (50 μM, 30 minutes) in LPS-stimulated BV-2 cells (n = 6, **P < 0.01 versus
control; *P < 0.05 or **P < 0.01 versus the LPS alone-treated group). NS, no significance. All data were shown as mean ± standard error.
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BV-2 cells (Figure 5C and D). To initiate gene transcription,
active NF-κB must enter nuclei. To investigate whether
TSG treatment could influence the nuclear transport of
NF-κB, we analyzed the change in NF-κB level in the cyto-
plasm and nucleus in BV-2 cells stimulated with LPS. As
shown in Figure 6A, B, C, and D, NF-κB p65 was present
predominantly in the cytoplasm in un-stimulated cells. LPS
incubation resulted in NF-κB nuclear translocation, but this
translocation was not affected by TSG pretreatment
(50 μM, 30 minutes) (Figure 6A, B, C, and D). Because
IκB-α degradation and NF-κB activation are reported to
be mediated by MAPK signals [18-20], we then checked
the influence of TSG in MAPK activation including the
phosphorylation of ERK1/2, JNK, and p38. We found
that TSG did not suppress the increase in the phos-
phorylation level of ERK1/2, JNK, and p38 in LPS-
Figure 5 Effects of TSG on lipopolysaccharide (LPS)-initiated inhibitor of κB α (IκB-α) degradation and nuclear factor κB (NF-κB)
phosphorylation in BV-2 cells. (A) LPS-induced IκB-α degradation was not altered in TSG (50 μM, 30 minutes)-incubated BV-2 cells. (B) Quantitative
analysis of the effect of TSG on IκB-α degradation in LPS-treated cells (n = 3, *P < 0.05 versus control). (C) LPS-induced NF-κB phosphorylation was also
not changed by TSG treatment (50 μM, 30 minutes). (D) Quantitative analysis of the effect of TSG on NF-κB phosphorylation level in LPS-treated cells
(n = 3, *P < 0.05 versus control). All data were shown as mean ± standard error. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Figure 4 Role of TSG in mRNA formation of pro-inflammatory factors in BV-2 cells. Quantitative analysis of the mRNA level of inducible
nitric oxide (iNOS) (A), TNF-α (B), and IL-6 (C) in cells upon lipolysaccharide (LPS) with or without TSG pretreatment (30 minutes, 50 μM, n = 3,
**P < 0.01 versus control; *P < 0.05 versus the LPS alone-treated group). NS, no significance. All data were shown as mean ± standard error.
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stimulated BV-2 cells (Figure 6E). Taken together, our
findings indicate that the effect of TSG on induction of
pro-inflammatory factors in BV-2 cells was not due to
the inhibition of MAPK-IκB-α-NF-κB signals.
TSG attenuates the binding activity of NF-κB in LPS-
stimulated BV-2 cells
As TSG did not appear to affect MAPK-IκB-α-NF-κB
activation, we then tested a possibility that TSG might
inhibit pro-inflammatory factor transcription by directly
interfering with NF-κB binding to its DNA element. To
explore this possibility, BV-2 cells were stimulated with
LPS to activate NF-κB. Binding of active NF-κB with la-
beled DNA oliogos corresponding to its promoter was
monitored in the absence or presence of TSG. As shown
in Figure 7A, LPS induced a dramatic increase in NF-κB
binding activity in nuclei. This effect was abolished by
TSG in a dose-dependent manner. To further confirm
this effect, we performed ChIP assays on the iNOS pro-
moter in stimulated cells with or without pretreatment
with TSG (50 μM). As shown in Figure 7B and 7C, LPS-
elicited NF-κB binding to the iNOS promoter was signifi-
cantly reduced by TSG pretreatment (50 μM, 30 minutes).
These data indicate that TSG primarily interferes with
binding of NF-κB to its DNA element in BV-2 microglia.
TSG reduces the induction of iNOS in LPS-stimulated
primary microglia
Finally, we performed experiments to ascertain whether
the major findings in BV-2 cells also occur in primary
microglia. As expected, pretreatment of primary micro-
glia with TSG (50 μM, 30 minutes) reduced the iNOS
expression (Figure 8A and B). Similar to what was ob-
served in BV-2 cells, NO production in LPS-stimulated
primary microglia was also reduced by TSG treatment
(50 μM, 30 minutes) (Figure 8C). Consequently, TSG
Figure 6 Effects of TSG on the nuclear translocation of nuclear factor κB (NF-κB) and activation of mitogen-activated protein kinase
(MAPK) signals in BV-2 cells. (A) Effects of TSG on NF-κB expression in the cytoplasm in lipolysaccharide (LPS)/TSG-treated BV-2 cells. (B) Quantitative
analysis of NF-κB amount in the cytoplasm (n = 3, *P < 0.05 versus control or the TSG alone-treated group). (C) Effects of TSG on NF-κB expression in
the nucleus in LPS/TSG-treated BV-2 cells. (D) Quantitative analysis of the amount of NF-κB in the nucleus (n = 3, *P < 0.05 versus control, **P < 0.01
versus the TSG alone-treated group). (E) Representative images showing the effect of TSG (50 μM, 30 minutes) on LPS-induced increase in ERK1/2, JNK,
and p38 phosphorylation level in BV-2 cells. Experiments were performed three times independently. All data were shown as mean ± standard error.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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reduced the percentage of apoptotic nuclei in hippocampal
neurons injured by primary microglia-derived conditioned
medium (Figure 8D and E). Moreover, we observed an in-
hibitory effect of TSG on the binding of NF-κB to its DNA
element in the nucleus in LPS-stimulated primary microglia
(Figure 8F). Collectively, these data demonstrate that TSG
attenuates the inflammatory response in primary microglia
by suppressing the DNA binding activity of NF-κB.
Discussion
The endotoxin- or pathogen-mediated induction of pro-
inflammatory factors in microglia are implicated in
pathophysiological processes of neurotoxicity [33-35].
Numerous anti-oxidative molecules have been shown to
protect neurons from cell toxicity in inflammatory disor-
ders by attenuating the production of pro-inflammatory
factors such as NO, TNF-α, and IL-6 in microglia
[21,22,36]. TSG, an active component of the rhizome ex-
tract from Polygonummultiflorum, exhibits its function
through anti-inflammation [24], anti-apoptosis [26], and
anti-oxidation [37]. In this study, we found that TSG im-
pairs LPS-mediated inflammatory response in microglia.
This effect was exemplified by the decrease in the pro-
duction of pro-inflammatory factors as well as the DNA
binding activity of NF-κB in LPS/TSG-stimulated micro-
glia. This finding underscores the importance of TSG in
regulation of inflammation, and extends the role of TSG
beyond a cardiovascular protective molecule to a modu-
lator of microglia activation. Recently, interesting work
reported that TSG prevents the overexpression of α-
synuclein in APPV717I transgenic mice with Alzheimer’s
disease (AD), strongly showing a potential role of TSG
in prevention or treatment of AD [38]. Together with
the fact that microglia are believed to mediate the devel-
opment of AD [39,40] and that the damage of neurons
in neurodegenerative disorders is usually secondary to
microglia activation [41,42], we believe that our data
may provide evidence to clarify how TSG exerts its pro-
tective effect in AD. In vivo experiments designed to in-
vestigate the role and mechanism of TSG in different
neurodegenerative disorders in the CNS are in progress.
The functional consequence of microglia activation de-
pends on the induction and release of pro-inflammatory
factors. The appropriate amount of pro-inflammatory factor
is indispensable for various physiological processes, such as
neuronal protection [14,15] and synaptic plasticity [31].
However, overwhelmingly generated pro-inflammatory fac-
tors can act as neurotoxins and cause neuronal injury
[5,6,43,44]. Strategies to inhibit the excessive production of
pro-inflammatory factors are crucial to attenuate the neuro-
toxicity induced by inflammatory events. In the present
study, we showed that TSG reduces the content of NO,
TNF-α, and IL-6, and this reduction protects the hippo-
campal neurons from microglia-conditioned medium-
induced cell injury. This finding about the role of TSG in
induction of pro-inflammatory factors in microglia and pro-
tection of hippocampal neurons from inflammatory stimu-
lation provides a new insight into the pharmacological role
of TSG in inflammatory disorders.
Blockade of gene transcription in stimulated inflamma-
tory cells is often due to one or multiple interruptions in
the signaling transduction from the stimuli to the corre-
sponding transcriptional cytokines. In LPS signals, the
MAPKs-IKK-IκB-α-NF-κB pathway is downstream of LPS
signaling transduction [15,34]. IκB-α is phosphorylated by
IKK, which then leads to the degradation of IκB-α and the
translocation of NF-κB from the cytoplasm to nucleus.
However, we found that although TSG inhibited pro-
inflammatory factor gene-transcription in microglia, it
failed to affect LPS-induced IκB-α degradation and NF-κB
phosphorylation or nuclear translocation. Neither did we
observe any significant effect on the LPS-induced increase
in ERK1/2, JNK, or the p38 phosphorylation levels. It indi-
cates that TSG might affect the inflammatory response in
microglia by a mechanism downstream of the nuclear
translocation of NF-κB. In fact, our results showed that
the increase in DNA binding activity of NF-κB in LPS-
stimulated microglia was remarkably suppressed by TSG.
Figure 7 TSG attenuates the binding of nuclear factor-κB
(NF-κB) to its DNA element in BV-2 cells. (A) Quantitative analysis
of the effect of TSG on the binding of NF-κB to its DNA element in
BV-2 cells (n = 5, **P < 0.01 versus the lipolysaccharide (LPS) alone-
treated group). (B) ChIP assays showed that TSG treatment (50 μM,
30 minutes) markedly reduced the binding of NF-κB to the inducible
nitric oxide (iNOS) promoter in LPS-treated cells. The chromatin
was immunoprecipitated by using the anti-NF-κB p65 antibody.
(C) Quantitative analysis of the effect of TSG on the binding of NF-κB
to the iNOS promoter in BV-2 cells (n = 3, **P < 0.01 versus control). NS,
no significance. All data were shown as mean ± standard error.
Huang et al. Journal of Neuroinflammation 2013, 10:129 Page 9 of 12
http://www.jneuroinflammation.com/content/10/1/129
Moreover, the reduction in active NF-κB from binding to
the iNOS promoter in the ChIP assay further confirmed
the function of TSG. In general, these data provide a
plausible explanation why the gene transcription of pro-
inflammatory factors is inhibited, despite the fact that acti-
vation of MAPK-IκB-α-NF-κB signals is not perturbed in
TSG/LPS co-treated cells. However, as we did not check
the influence of TSG in the binding of NF-κB to TNF-α
and IL-6 promoters, to some extent these conclusions
limit our observations for the role of TSG in inflammatory
response in microglia. Some previous studies associated
with the interaction between NF-κB and TNF-α and IL-6
promoters might give us evidence to offset the limitation.
For example, a 120-bp TNF-α promoter was found to pos-
sess a binding site for NF-κB [45], and the promoter
region of the IL-6 gene was confirmed to have a putative
NF-κB binding site [46].
It is worth noting that our above observations in
microglia are inconsistent with the in vitro oxygen glu-
cose deprivation/reperfusion (OGD/R)-stimulated neurons
where the TSG-mediated reduction in iNOS expression
and brain infarct volume is mediated by the inhibition of
nuclear translocation of NF-κB [26]. However, because
there are large differences between in vitro and in vivo
micro-environments and the damage of neurons in the
in vivo conditions usually occurs following excessive acti-
vation of microglia, we tend to suppose that the TSG-
mediated reduction in infarct volume after brain ischemia
might be mediated by the attenuation of inflammatory re-
sponse in microglia with a mechanism that is different
Figure 8 TSG reduces the induction of inducible nitric oxide (iNOS) in lipolysaccharide (LPS)-stimulated primary microglia and protects
the hippocampal neurons from primary microglia conditioned medium-induced cell injury. (A) Representative images showing that TSG
treatment (30 minutes, 50 μM) inhibited iNOS expression in primary microglia. (B) Quantitative analysis of the iNOS expression in primary
microglia in LPS/TSG-treated cells (n = 5, **P < 0.01 versus control or the LPS alone-treated group). (C) Quantitative analysis of NO content in LPS/
TSG-treated cells (n = 5, **P < 0.01 versus control; *P < 0.05 versus the LPS alone-treated group). (D) TSG treatment (30 minutes, 50 μM) inhibited
the increase in apoptotic nuclei in hippocampal neurons induced by primary microglia-derived conditioned medium. (E) Quantitative analysis of
apoptotic nuclei in LPS/TSG-treated cells (n = 5, **P < 0.01 versus control; *P < 0.05 versus the LPS alone-treated group). (F) Quantitative analysis
showing that the LPS-induced increase in the binding of nuclear factor -κB (NF-κB) to its DNA element in primary microglia was attenuated by
TSG treatment at the concentrations of 10 and 50 μM (n = 5, *P < 0.05 versus the LPS alone-treated group). NS, no significance; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase. All data were shown as mean ± standard error.
Huang et al. Journal of Neuroinflammation 2013, 10:129 Page 10 of 12
http://www.jneuroinflammation.com/content/10/1/129
from that in neurons. That is, TSG may protect the brain
tissues from ischemia by impairing the DNA binding ac-
tivity of NF-κB. However, how this mechanism works in
microglia is not clear. We notice that though resveratrol, a
polyphenolicphytoalexin found in grapes, fruits, and root
extracts of the weed Polygonumcuspidatum [47], has simi-
lar characteristics in structure to TSG [48,49], it exhibits
distinct mechanisms in regulation of inflammatory re-
sponse in microglia. For example, resveratrol was reported
to decrease the production of pro-inflammatory factors
primarily by impairing the phosphorylation and nuclear
translocation of NF-κB [49,50]. This difference, combined
with the highly similar structure of TSG and resveratrol,
might help us to further clarify the exact mechanism of
TSG in inflammatory response.
In summary, this study identifies a role for TSG in the
induction of pro-inflammatory factors in microglia by a
mechanism that is independent of MAPK activation,
IκB-α degradation, and NF-κB phosphorylation/nuclear
translocation, but probably relies on the repression of
NF-κB binding activity.
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